Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ: MNMD )

7.160 +0.145 (+2.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,... 
Via Talk Markets
3 Psychedelic Stocks to Ride to the Moon and Beyond
Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market. 
Via InvestorPlace
Exposures Product Safety
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals. 
Via InvestorPlace
Exposures Product Safety
Clinical-Stage BioTech Drug Stocks Declined 13% In June
Our BioTech Drug Stocks Portfolio was DOWN 13.2% in June. Before proceeding read 
Via Talk Markets
MindMed to be Included in Russell 2000® and Russell 3000® Indexes
From Mind Medicine Inc.
Via Business Wire
Groundbreaking Fentanyl Vaccine Being Developed To Prevent Fatal Overdoses, Startup Secures $10M
The initiative focuses on commercializing academic research aimed at preventing deadly fentanyl from reaching the brain. 
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they... 
Via Talk Markets
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From Mind Medicine Inc.
Via Business Wire
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
From Mind Medicine
Via Business Wire
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
Discover top strong buy penny stocks, poised for impressive gains as market indices climb, offering unique opportunities. 
Via InvestorPlace
Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why
Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA. 
Via Talk Markets
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit, with CYBN, MNMD, and ATAI down. FDA not bound by decision. 
Via Benzinga
Exposures Product Safety
What's Going On With MindMed And Psychedelic Stocks?
Mind Medicine (MindMed) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stress disorder (PTSD).... 
Via Benzinga
DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Why Stitch Fix Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Via Benzinga
MindMed to Participate in June Conferences
From Mind Medicine Inc.
Via Business Wire
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our... 
Via Talk Markets
The Time Traveler’s Portfolio: 3 Stocks to Buy Now for Massive Returns by 2034
These long-term stocks to buy may seem speculative today, but so did Nvidia in 2024 -- and they may match the chipmaker's returns by 2034. 
Via InvestorPlace
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Jim Cramer: This Industrial Company Is 'Absolutely Terrific', Recommends Buying Modine Manufacturing
Regarding Hertz, Jim Cramer said, "I don't want you to sell, and I don't want you to double down. Let's just see if it can't go higher." 
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
Seritage Growth Properties Posts Q1 Loss, Joins Fortrea Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May
Some of the top Russell 2000 stocks to buy are those that few investors pay attention to but offer great potential nonetheless. 
Via InvestorPlace
MindMed to Participate at May Investor Conferences
From MindMed
Via Business Wire
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US
From Mind Medicine (MindMed) Inc.
Via Business Wire
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot. 
Via InvestorPlace
MNMD Stock Earnings: Mind Medicine Misses EPS for Q1 2024
MNMD stock results show that Mind Medicine missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
MindMed Reports First Quarter 2024 Financial Results and Business Updates
From MindMed
Via Business Wire
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.